NCT02658084TERMINATEDanonymous

A Phase I/II Study to Evaluate the Safety and Efficacy of Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer

Sponsor

Source record

University of Miami

Phase

Source record

PHASE1

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Vinorelbine, Trastuzumab Emtansine

Indication / condition

AI-normalized

Breast Cancer

Intervention

Source record

Vinorelbine, Trastuzumab Emtansine

Source & freshness

Source record

NCT ID

NCT02658084

Original source

ClinicalTrials.gov

Source last updated

Apr 17, 2019

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT02658084

Title

A Phase I/II Study to Evaluate the Safety and Efficacy of Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer

Sponsor

University of Miami

Status

TERMINATED

Phase

PHASE1

Condition raw

Breast Cancer

Condition normalized

Breast Cancer

Modality raw

Breast Cancer

Modality normalized

monoclonal antibody

Target raw

Vinorelbine, Trastuzumab Emtansine

Target normalized

Vinorelbine, Trastuzumab Emtansine

Interventions

Vinorelbine, Trastuzumab Emtansine

Public preview

Source record

The study proposes to evaluate the safety and efficacy of the combination of trastuzumab emtansine (T-DM1) and vinorelbine in HER2+ metastatic breast cancer patients.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase I/II Study to Evaluate the Safety and Efficacy of Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02658084

Status

TERMINATED

Phase

PHASE1

Sponsor

University of Miami

Executive brief

Investment-Ready Snapshot

The study proposes to evaluate the safety and efficacy of the combination of trastuzumab emtansine (T-DM1) and vinorelbine in HER2+ metastatic breast cancer patients.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedApr 17, 2019

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02658084

Indication

Breast Cancer

Modality

monoclonal antibody

Target

Vinorelbine, Trastuzumab Emtansine

Intervention

Vinorelbine, Trastuzumab Emtansine

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.